Growth factor therapy for cardiac repair: an overview of recent advances and future directions

Biophysics Reviews
Samuel J White, James J H Chong

Abstract

Heart disease represents a significant public health burden and is associated with considerable morbidity and mortality at the level of the individual. Current therapies for pathologies such as myocardial infarction, cardiomyopathy and heart failure are unable to repair damaged tissue to an extent that provides restoration of function approaching that of the pre-diseased state. Novel approaches to repair and regenerate the injured heart include cell therapy and the use of exogenous factors. Improved understanding of the role of growth factors in endogenous cardiac repair processes has motivated the investigation of their potential as therapeutic agents for cardiac pathology. Despite the disappointing performance of other growth factors in historical clinical trials, insulin-like growth factor 1 (IGF-1), neuregulin and platelet-derived growth factor (PDGF) have recently emerged as new candidate therapies. These growth factors elicit tissue repair through anti-apoptotic, pro-angiogenic and fibrosis-modulating mechanisms and have produced clinically significant functional improvement in preclinical studies. Early human trials suggest that IGF-1 and neuregulin are well tolerated and yield dose-dependent benefit, warranting progress...Continue Reading

References

Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·M BuerkeA M Lefer
Dec 19, 1998·European Heart Journal·J IsgaardB A Bengtsson
Oct 6, 1999·The Annals of Thoracic Surgery·J F SymesJ M Isner
Mar 19, 2003·Circulation·Timothy D HenryUNKNOWN VIVA Investigators
Dec 24, 2003·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Falk-Udo SackPhilipp A Schnabel
Jan 15, 2004·American Journal of Physiology. Endocrinology and Metabolism·Simona I Chisalita, Hans J Arnqvist
Oct 26, 2005·Journal of Molecular and Cellular Cardiology·Todd C McDevittCharles E Murry
Dec 17, 2005·The Journal of Clinical Investigation·Patrick C H HsiehRichard T Lee
Feb 24, 2006·Cell and Tissue Research·M DobaczewskiN G Frangogiannis
Nov 30, 2006·PLoS Medicine·Colin D Mathers, Dejan Loncar
Dec 13, 2006·Journal of the American College of Cardiology·Pawel ZymekNikolaos G Frangogiannis
Feb 26, 2008·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Jione KangPenny S Thomas
Jun 6, 2008·Journal of Virology·Magalie Penaud-BudlooRichard O Snyder
Nov 26, 2008·Circulation Research·Massimiliano GnecchiVictor J Dzau
Feb 10, 2009·Atherosclerosis·Gian Paolo FadiniAngelo Avogaro
Feb 17, 2009·Developmental Cell·Masaki IedaDeepak Srivastava
Apr 9, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Duncan J StewartUNKNOWN NORTHERN Trial Investigators
Jul 11, 2009·Journal of Molecular Endocrinology·S I ChisalitaH J Arnqvist
Dec 30, 2009·The Journal of Clinical Investigation·Chien-hui LiaoIssei Komuro
Mar 24, 2010·Journal of Molecular and Cellular Cardiology·Marius VantlerWolfram-H Zimmermann
Aug 24, 2010·Journal of Molecular and Cellular Cardiology·Maria MirotsouVictor J Dzau

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic

Software Mentioned

AMI
EUROINJECT
BioRender
ONE
RESUS

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

Nihon rinsho. Japanese journal of clinical medicine
Kazuo Komamura
International Journal of Cardiology
Marc S Penn, Udit Agarwal
Biomedical Sciences Instrumentation
La Toya Ross RichardsMichelle Tucci
© 2021 Meta ULC. All rights reserved